期刊
MOLECULAR NUTRITION & FOOD RESEARCH
卷 62, 期 7, 页码 -出版社
WILEY
DOI: 10.1002/mnfr.201700931
关键词
Crohn's disease; dendritic cells; gastrointestinal tract; inflammatory bowel disease; ulcerative colitis
资金
- Spanish Ministry of Economy [SAF2014-56642-JIN]
- Asociacion Espanola de Gastroenterologia
- Spanish Ministry of Health [PIE13/00041]
- Asociacion Castellana de Aparato Digetivo (Beca ACAD)
- MSD
- Abbvie
- Hospira
- Pfizer
- Takeda
- Janssen
- Ferring
- Shire Pharmaceuticals
- Dr. Falk Pharma
- Tillotts Pharma
- Otsuka
- Kern Pharma
- Biogen
- Roche
- Faes Farma
- Chiesi
- Casen Fleet
- Gebro Pharma
- Otsuka Pharmaceutical
- Vifor Pharma
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a serious, costly, and persistent health problem with an estimated prevalence in Western countries around 0.5% of the general population; its socioeconomic impact is comparable with that for chronic diseases such as diabetes. Conventional treatment involves escalating drug regimens with concomitant side effects followed, in some cases, by surgical interventions, which are often multiple, mainly in Crohn's disease. The goal of finding a targeted gut-specific immunotherapy for IBD patients is therefore an important unmet need. However, to achieve this goal we first must understand how dendritic cells (DC), the most potent antigen present cells of the immune system, control the immune tolerance in the gastrointestinal tract and how their properties are altered in those patients suffering from IBD. In this review, we summarize the current available information regarding human intestinal DC subsets composition, phenotype, and function in the human gastrointestinal tract describing how, in the IBD mucosa, DC display pro-inflammatory properties, which drive disease progression. A better understanding of the mechanisms inducing DC abnormal profile in IBD may provide us with novel tools to perform tissue specific immunomodulation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据